Cannabinoid Compounds May Inhibit Colon Cancer Growth

Certain cannabinoid (CBD) compounds may inhibit the growth of colon cancer cells, according to researchers at Penn State College of Medicine.
Their study, published in Cannabis and Cannabinoid Research, tested the effects of 370 synthetic cannabinoid compounds on 7 types of human colon cancer cells. Researchers incubated the cells in the lab for 8 hours before introducing the cannabinoid compounds for an additional 48 hours.
Compounds such as THC and CBD showed little to no effect when tested, yet researchers found 10 other compounds that were successful at reducing cell viability in almost all of the 7 tested types of colon cancer. Although the compounds have been identified to hinder cancer cell divide, researchers are still unsure of how they do it.
Kent Vrana, PhD, co-author of the study, explained that since the study helped to identify these potentially anti-cancer compounds, further research could alter them to make the compounds even more potent against cancer cells. He continued, "and then eventually, we can explore the potential for using these compounds to develop drugs for treating cancer."
According to the National Cancer Institute, there were an estimated 140,250 newly diagnosed colorectal cancer cases and 50,630 deaths in 2018. Medical cannabis has been used in recent years as an immediate form of care, and prior studies suggest that it has cancer–growth inhibiting properties. This new research pinpointed which compounds are more likely to inhibit cancer cell growth in more rapidly dividing areas, such as colon cells.
Vrana continued, "every time a cell divides, there's the chance that it will mutate and keep dividing when it shouldn't, which is how cancers can start. So, if we block that signal that's telling cancer cells to continue to divide, that could be a way to stop that cancer."

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent.
Top news of the day from across the health care landscape.
Photobiomodulation therapy found effective for the prevention of oral mucositis caused by radiation therapy.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.